Article
A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus.
The Journal of infectious diseases - 15 Mar 2004
Drusano G L, Preston S L
Abstract excerpt
The therapeutic response among patients infected with hepatitis C virus (HCV) of genotype 1 remains suboptimal. We examined a large database of patients treated with combination therapy (ribavirin plus an interferon [IFN]). We hypothesized that the longer the duration that the virus load was rendered undetectable in serum, the better would be the probability of a sustained viral response (SVR). A model predicting...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.